Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Fluids and Barriers of the CNS
Published in: Fluids and Barriers of the CNS 1/2023

Open Access 01-12-2023 | Review

Methylglyoxal, a highly reactive dicarbonyl compound, as a threat for blood brain barrier integrity

Authors: Eline Berends, Robert J van Oostenbrugge, Sébastien Foulquier, Casper G Schalkwijk

Published in: Fluids and Barriers of the CNS | Issue 1/2023

Login to get access

Abstract

The brain is a highly metabolically active organ requiring a large amount of glucose. Methylglyoxal (MGO), a by-product of glucose metabolism, is known to be involved in microvascular dysfunction and is associated with reduced cognitive function. Maintenance of the blood-brain barrier (BBB) is essential to maintain optimal brain function and a large amount of evidence indicates negative effects of MGO on BBB integrity. In this review, we summarized the current literature on the effect of MGO on the different cell types forming the BBB. BBB damage by MGO most likely occurs in brain endothelial cells and mural cells, while astrocytes are most resistant to MGO. Microglia on the other hand appear to be not directly influenced by MGO but rather produce MGO upon activation. Although there is clear evidence that MGO affects components of the BBB, the impact of MGO on the BBB as a multicellular system warrants further investigation. Diminishing MGO stress can potentially form the basis for new treatment strategies for maintaining optimal brain function.
Literature
1.
2.
3.
4.
5.
6.
7.
Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol 18:123–31.
8.
Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS Immune Privilege. Trends Immunol 36:569–77.
9.
Buckley MW. McGavern DB Immune dynamics in the CNS and its barriers during homeostasis and disease*. Immunol Rev 306:58–75.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
Baskaran S, Prasanna D, Balasubramanian KA. Formation of methylglyoxal by bacteria isolated from human faeces.
34.
Degen J, Vogel M, Richter D et al. Metabolic transit of dietary Methylglyoxal. In: Journal of Agricultural and Food Chemistry. pp 10253–10260.
35.
36.
Hernandez-Castillo C, Shuck SC. Diet and obesity-Induced Methylglyoxal Production and Links to Metabolic Disease. Chem Res Toxicol 34:2424–40.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
Zhou WJ, Gui QF, Wu Y, Yang YM. Tanshinone IIA protects against methylglyoxal-induced injury in human brain microvascular endothelial cells. Int J Clin Exp Med. 2015;8:1985–92.PubMedPubMedCentral
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Weidemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ 15:621–7.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
Dhananjayan K, Gunawardena D, Hearn N, et al. Activation of macrophages and Microglia by Interferon-γ and Lipopolysaccharide increases Methylglyoxal production: a new mechanism in the development of Vascular Complications and Cognitive decline in type 2 Diabetes Mellitus? J Alzheimer’s Disease. 2017;59:467–79. https://​doi.​org/​10.​3233/​JAD-161152CrossRef
129.
130.
131.
132.
133.
134.
135.
136.
137.
Kuhla B, Lüth HJ, Haferburg D et al. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s Disease. In: Annals of the New York Academy of Sciences. New York Academy of Sciences, pp 211–6.
138.
139.
140.
141.
142.
Metadata
Title
Methylglyoxal, a highly reactive dicarbonyl compound, as a threat for blood brain barrier integrity
Authors
Eline Berends
Robert J van Oostenbrugge
Sébastien Foulquier
Casper G Schalkwijk
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Fluids and Barriers of the CNS / Issue 1/2023
Electronic ISSN: 2045-8118
DOI
https://doi.org/10.1186/s12987-023-00477-6

Other articles of this Issue 1/2023

Fluids and Barriers of the CNS 1/2023 Go to the issue

Research

Concentration gradients of monoamines, their precursors and metabolites in serial lumbar cerebrospinal fluid of neurologically healthy patients determined with a novel LC–MS/MS technique

Research

The maturation of iPS cell-derived brain microvascular endothelial cells by inducible-SOX18 expression

Correction

Correction to: The choroid plexus acts as an immune cell reservoir and brain entry site in experimental autoimmune encephalomyelitis

Review

A scoping review of the discrepancies in the measurement of cerebral blood flow in idiopathic intracranial hypertension: oligemia, euvolemia or hyperemia?

Research

Non-invasive flow mapping of parasagittal meningeal lymphatics using 2D interslice flow saturation MRI

Research

miRNA-ome plasma analysis unveils changes in blood–brain barrier integrity associated with acute liver failure in rats